Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma

Molecular Therapy

Volumn 18, Issue 2, 2010, Pages 275-284

  Altomonte, Jennifer ^a   Marozin, Sabrina ^a   Schmid, Roland M ^a   Ebert, Oliver ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; ONCOLYTIC VIRUS; PROTEIN F3AA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER SURVIVAL; CELL SPECIFICITY; CONTROLLED STUDY; DRUG DOSE ESCALATION; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MALE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PARENCHYMA; PROMOTER REGION; RAT; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CHICKENS; GENETIC VECTORS; HUMANS; INTERFERON TYPE I; LIVER NEOPLASMS; MALE; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; RATS;

NEWCASTLE DISEASE VIRUS; RATTUS NORVEGICUS;

EID: 76349119010     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.231     Document Type: Article

References (49)

1. Parkin, DM, Bray, F, Ferlay, J and Pisani, P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156. (Pubitemid 32911406)
2. El-Serag, HB, Mason, AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
3. Dyer, Z, Peltekian, K and van Zanten, SV (2005). Review article: the changing epidemiology of hepatocellular carcinoma in Canada. Aliment Pharmacol Ther 22: 17-22.
4. El-Serag, HB, Davila, JA, Petersen, NJ and McGlynn, KA (2003). The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139: 817-823.
5. Deuffc, S, Poynard, T, Buffat, L and Valleron, AJ (1998). Trends in primary liver cancer. Lancet 351: 214-215.
6. Mathurin, P, Rixe, O, Carbonell, N, Bernard, B, Cluzel, P, Bellin, MF, et al. (1998). Review article: overview of medical treatments in unresectable hepatocellular carcinoma\-an impossible meta-analysis? Aliment Pharmacol Ther 12: 111-126.
7. Llovet, JM, Burroughs, A and Bruix, J (2003). Hepatocellular carcinoma. Lancet 362: 1907-1917.
8. Lorence, RM, Katubig, BB, Reichard, KW, Reyes, HM, Phuangsab, A, Sassetti, MD, et al. (1994). Complete regression of human fbrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54: 6017-6021. (Pubitemid 24378619)
9. Peng, KW, Ahmann, GJ, Pham, L, Greipp, PR, Cattaneo, R and Russell, SJ (2001). Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98: 2002-2007.
10. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N, et al. (2000). Exploiting tumor-specifc defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
11. Reichard, KW, Lorence, RM, Cascino, CJ, Peeples, ME, Walter, RJ, Fernando, MB, et al. (1992). Newcastle disease virus selectively kills human tumor cells. J Surg Res 52: 448-453.
12. Balachandran, S, Barber, GN. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 2000;50: 135-138.
13. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S, et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
14. Park, MS, García-Sastre, A, Cros, JF, Basler, CF and Palese, P (2003). Newcastle disease virus V protein is a determinant of host range restriction. J Virol 77: 9522-9532.
15. Hotte, SJ, Lorence, RM, Hirte, HW, Polawski, SR, Bamat, MK, O'Neil, JD, et al. (2007). An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 13: 977-985.
16. Freeman, AI, Zakay-Rones, Z, Gomori, JM, Linetsky, E, Rasooly, L, Greenbaum, E, et al. (2006). Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13: 221-228.
17. Csatary, LK, Gosztonyi, G, Szeberenyi, J, Fabian, Z, Liszka, V, Bodey, B, et al. (2004). MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67: 83-93.
18. Nemunaitis, J (2002). Live viruses in cancer treatment. Oncology (Williston Park, NY) 16: 1483-1492; discussion 1495.
19. Vigil, A, Park, MS, Martinez, O, Chua, MA, Xiao, S, Cros, JF, et al. (2007). Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67: 8285-8292.
20. Janke, M, Peeters, B, de Leeuw, O, Moorman, R, Arnold, A, Fournier, P, et al. (2007). Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther 14: 1639-1649.
21. Lamb, RA (1993). Paramyxovirus fusion: a hypothesis for changes. Virology 197: 1-11.
22. Bateman, AR, Harrington, KJ, Kottke, T, Ahmed, A, Melcher, AA, Gough, MJ, et al. (2002). Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 62: 6566-6578.
23. Sergel, TA, McGinnes, LW and Morrison, TG (2000). A single amino acid change in the Newcastle disease virus fusion protein alters the requirement for HN protein in fusion. J Virol 74: 5101-5107.
24. Li, J, Melanson, VR, Mirza, AM and Iorio, RM (2005). Decreased dependence on receptor recognition for the fusion promotion activity of L289A-mutated Newcastle disease virus fusion protein correlates with a monoclonal antibody-detected conformational change. J Virol 79: 1180-1190.
25. Ebert, O, Shinozaki, K, Kournioti, C, Park, MS, García-Sastre, A and Woo, SL (2004). Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 64: 3265-3270.
26. Shin, EJ, Chang, JI, Choi, B, Wanna, G, Ebert, O, Genden, EM, et al. (2007). Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg 136: 811-817.
27. Sakaguchi, T, Matsuda, Y, Kiyokage, R, Kawahara, N, Kiyotani, K, Katunuma, N, et al. (1991). Identifcation of endoprotease activity in the trans Golgi membranes of rat liver cells that specifcally processes in vitro the fusion glycoprotein precursor of virulent Newcastle disease virus. Virology 184: 504-512.
28. Peeters, BP, de Leeuw, OS, Koch, G and Gielkens, AL (1999). Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 73: 5001-5009.
29. de Leeuw, OS, Hartog, L, Koch, G and Peeters, BP (2003). Effect of fusion protein cleavage site mutations on virulence of Newcastle disease virus: non-virulent cleavage site mutants revert to virulence after one passage in chicken brain. J Gen Virol 84: 475-484.
30. Park, MS, Steel, J, García-Sastre, A, Swayne, D and Palese, P (2006). Engineered viral vaccine constructs with dual specifcity: avian infuenza and Newcastle disease. Proc Natl Acad Sci USA 103: 8203-8208.
31. Zamarin, D, Vigil, A, Kelly, K, García-Sastre, A and Fong, Y (2009). Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther 16: 796-804.
32. Krishnamurthy, S, Takimoto, T, Scroggs, RA and Portner, A (2006). Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80: 5145-5155.
33. Keskinen, P, Nyqvist, M, Sareneva, T, Pirhonen, J, Melén, K and Julkunen, I (1999). Impaired antiviral response in human hepatoma cells. Virology 263: 364-375.
34. Marozin, S, Altomonte, J, Stadler, F, Thasler, WE, Schmid, RM and Ebert, O (2008). Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther 16: 1789-1797.
35. Shinozaki, K, Ebert, O, Kournioti, C, Tai, YS and Woo, SL (2004). Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 9: 368-376.
36. Bateman, A, Bullough, F, Murphy, S, Emiliusen, L, Lavillette, D, Cosset, FL, et al. (2000). Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 60: 1492-1497.
37. Yun, CO (2008). Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy. Curr Opin Mol Ther 10: 356-361.
38. Heise, CC, Williams, A, Olesch, J and Kirn, DH (1999). Effcacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 6: 499-504.
39. Melcher, A, Todryk, S, Hardwick, N, Ford, M, Jacobson, M and Vile, RG (1998). Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 4: 581-587.
40. Welsh, RM (1986). Regulation of virus infections by natural killer cells. A review. Nat Immun Cell Growth Regul 5: 169-199.
41. Brutkiewicz, RR and Welsh, RM (1995). Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. J Virol 69: 3967-3971.
42. Orange, JS, Fassett, MS, Koopman, LA, Boyson, JE and Strominger, JL (2002). Viral evasion of natural killer cells. Nat Immunol 3: 1006-1012.
43. Liu, C, Lou, Y, Lizée, G, Qin, H, Liu, S, Rabinovich, B, et al. (2008). Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specifc T cell cross-priming and tumor regression in mice. J Clin Invest 118: 1165-1175.
44. Jarahian, M, Watzl, C, Fournier, P, Arnold, A, Djandji, D, Zahedi, S, et al. (2009). Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J Virol 83: 8108-8121.
45. Shinozaki, K, Ebert, O and Woo, SL (2005). Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41: 196-203.
46. Altomonte, J, Braren, R, Schulz, S, Marozin, S, Rummeny, EJ, Schmid, RM, et al. (2008). Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 48: 1864-1873.
47. Cassel, WA and Garrett, RE (1965). Newcastle disease virus as an Antineoplastic Agent. Cancer 18: 863-868.
48. Thasler, WE, Weiss, TS, Schillhorn, K, Stoll, PT, Irrgang, B and Jauch, KW (2003). Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank 4: 49-56.
49. Nakaya, T, Cros, J, Park, MS, Nakaya, Y, Zheng, H, Sagrera, A, et al. (2001). Recombinant Newcastle disease virus as a vaccine vector. J Virol 75: 11868-11873.